A Phase 2b study of Briquilimab in CSU.
Latest Information Update: 13 Jan 2025
Price :
$35 *
At a glance
- Drugs Briquilimab (Primary)
- Indications Chronic urticaria
- Focus Registrational; Therapeutic Use
- 13 Jan 2025 New trial record
- 08 Jan 2025 Final selection of doses for the Phase 2b study will be further informed by additional data at 180mg Q8W from the open-label extension study, as well as by further data from BEACON cohorts
- 08 Jan 2025 According to a Jasper Therapeutics media release, company expects to begin a registrational program in CSU with a Phase 2b study expected to commence in the second half of 2025.